Evidence map›Paper›PMID 38127913›Full record

ArticleBlood2024

Hemolysis-driven IFNα production impairs erythropoiesis by negatively regulating EPO signaling in sickle cell disease.

Yongshuai Han, Chengjie Gao, Yunfeng Liu, Huan Zhang, Shihui Wang, Huizhi Zhao, Weili Bao, Xinhua Guo, Francesca Vinchi, Cheryl Lobo and 6 more

Open access · greenAbstract read
In one paragraph

Article in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. CD163Biomarker research · 2026
    Article
  3. Article
  4. Whole Blood Transcriptomic Analysis of Sickle Cell Trait.European journal of haematology · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. The Immunology of Transfusion Medicine: Past, Present, and Future.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. PLK1 inhibition impairs erythroid differentiation.Frontiers in cell and developmental biology · 2024
    Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Yongshuai HanLaboratory of Membrane Biology, New York Blood Center, New York, NY.
Chengjie GaoLaboratory of Membrane Biology, New York Blood Center, New York, NY.
Yunfeng LiuLaboratory of Complement Biology, New York Blood Center, New York, NY.ORCID 0000-0002-9187-4146
Huan ZhangLaboratory of Membrane Biology, New York Blood Center, New York, NY.
Shihui WangLaboratory of Membrane Biology, New York Blood Center, New York, NY.
Huizhi ZhaoLaboratory of Membrane Biology, New York Blood Center, New York, NY.ORCID 0009-0005-5773-1968
Weili BaoLaboratory of Complement Biology, New York Blood Center, New York, NY.
Xinhua GuoLaboratory of Membrane Biology, New York Blood Center, New York, NY.ORCID 0009-0009-2359-0713
Francesca VinchiLaboratory of Iron Research, New York Blood Center, New York, NY.
Cheryl LoboLaboratory of Blood Borne Parasites, New York Blood Center, New York, NY.
Patricia ShiSickle Cell Clinical Research Program, New York Blood Center, New York, NY.ORCID 0000-0002-7954-0055
Avital MendelsonLaboratory of Stem Cell Biology and Engineering Research, New York Blood Center, New York, NY.ORCID 0000-0002-1120-9593
Larry LuchsingerLaboratory of Stem Cell Regenerative Research, New York Blood Center, New York, NY.ORCID 0000-0002-0063-1764
Hui ZhongLaboratory of Immune Regulation, New York Blood Center, New York, NY.
Karina YazdanbakhshLaboratory of Complement Biology, New York Blood Center, New York, NY.
Xiuli AnLaboratory of Membrane Biology, New York Blood Center, New York, NY.
New York Blood Center · US

Funding

Sickle cell bone marrow niche and regulation of platelet activation and erythropoiesisP01HL149626 · NHLBI · NEW YORK BLOOD CENTER · PI Karina Yazdanbakhsh · 2020 to 2026
$24.4M
Immune Pathophysiology of Sickle Cell DiseaseR35HL161239 · NHLBI · NEW YORK BLOOD CENTER · PI Karina Yazdanbakhsh · 2022 to 2026
$4.5M
Transfusion-driven hyperhemolysis in sickle cell diseaseR01HL165202 · NHLBI · NEW YORK BLOOD CENTER · PI Xiuli An, HUI ZHONG · 2023 to 2026
$3.2M
Use of forward Genetic approaches to identify Babesia receptorsR01HL140625 · NHLBI · NEW YORK BLOOD CENTER · PI AN, XIULI, LOBO, CHERYL ANN · 2018 to 2021
$2.8M
Hormetic ER Stress Regulation of Hematopoietic Stem Cell FunctionR01HL155574 · NHLBI · NEW YORK BLOOD CENTER · PI LUCHSINGER, LARRY L · 2021 to 2025
$2.5M
Transfusion-driven hyperhemolysis in sickle cell diseaseR56HL165202 · NHLBI · NEW YORK BLOOD CENTER · PI AN, XIULI, ZHONG, HUI · 2022 to 2022
$804k
NHLBI NIH HHS P01 HL149626NHLBI NIH HHS R01 HL140625NHLBI NIH HHS R01 HL155574NHLBI NIH HHS R01 HL165202NHLBI NIH HHS R35 HL161239NHLBI NIH HHS R56 HL165202
6 · The paper itself

Abstract

abstractDisordered erythropoiesis is a feature of many hematologic diseases, including sickle cell disease (SCD). However, very little is known about erythropoiesis in SCD. Here, we show that although bone marrow (BM) erythroid progenitors and erythroblasts in Hbbth3/+ thalassemia mice were increased more than twofold, they were expanded by only ∼40% in Townes sickle mice (SS). We further show that the colony-forming ability of SS erythroid progenitors was decreased and erythropoietin (EPO)/EPO receptor (EPOR) signaling was impaired in SS erythroid cells. Furthermore, SS mice exhibited reduced responses to EPO. Injection of mice with red cell lysates or hemin, mimicking hemolysis in SCD, led to suppression of erythropoiesis and reduced EPO/EPOR signaling, indicating hemolysis, a hallmark of SCD, and could contribute to the impaired erythropoiesis in SCD. In vitro hemin treatment did not affect Stat5 phosphorylation, suggesting that hemin-induced erythropoiesis suppression in vivo is via an indirect mechanism. Treatment with interferon α (IFNα), which is upregulated by hemolysis and elevated in SCD, led to suppression of mouse BM erythropoiesis in vivo and human erythropoiesis in vitro, along with inhibition of Stat5 phosphorylation. Notably, in sickle erythroid cells, IFN-1 signaling was activated and the expression of cytokine inducible SH2-containing protein (CISH), a negative regulator of EPO/EPOR signaling, was increased. CISH deletion in human erythroblasts partially rescued IFNα-mediated impairment of cell growth and EPOR signaling. Knocking out Ifnar1 in SS mice rescued the defective BM erythropoiesis and improved EPO/EPOR signaling. Our findings identify an unexpected role of hemolysis on the impaired erythropoiesis in SCD through inhibition of EPO/EPOR signaling via a heme-IFNα-CISH axis.

Indexed as

Anemia, Sickle CellErythropoiesisAnimalsHeminHemolysisHumansMiceReceptors, ErythropoietinSTAT5 Transcription FactorHeminReceptors, ErythropoietinSTAT5 Transcription Factor

Identifiers

PMID38127913
PMCPMC10950476
OpenAlexW4390043933

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.